Asset Class I-X, Type, Quantity, Business Model, Protection, Transaction Type, Unique Value Proposition, Key Paying Customers, Key Stakeholders and Unique Selling Point

« Live Notes and Conference Coverage in Real Time. COVID19 And The Impact on Cancer Patients Town Hall with Leading Oncologists; April 4, 2020

Recombinant Coronavirus Vaccines Delivered via Microneedle Array »

Asset Class I-X, Type, Quantity, Business Model, Protection, Transaction Type, Unique Value Proposition, Key Paying Customers, Key Stakeholders and Unique Selling Point

April 4, 2020 by 2012pharmaceutical

Asset

Classes

Type

Quantity

Business Model

Asset Protection

Transaction Type

Asset Class I

The Journal 3/3/2020 Views 1,723,051

5,742 articles on 3/3/2020

Valuation [$40M] done by Joel on Alex WP Data

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

B2B & B2B & B2C

Asset Class II

BioMed e-Series https://pharmaceuticalint elligence.com/2019- vista/global-market- penetration-forecast-for- each-volume-in-the-16- volume-biomed-e- series/

16 volumes

Valuation [$5M] done by Joel & Aviva

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

B2B & B2B & B2C

Asset Class III

eProceedings https://pharmaceuticalint elligence.com/2019- vista/e-proceedings-and- tweet-collections-per- conference-2013-2020- viewsdownloads-x-100- real-time-coverage-of- 60-events-by-ala-sjw/

60 events Valuation [$1.4M]

done by Dr. Williams &

Aviva

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

B2B & B2B & B2C

Asset Class IV

Platform, composition of methods and workflows for the content creation of scientific curations

TBD

Customized Platform Infrastructure, Building Tools for new products, venturing to new Disciplines beyond HealthCare,knowhow contracts in new geographies

internal and contracts

Asset

Classes

Type

Quantity

Business Model

Asset Protection

Transaction Type

Asset Class V

Gallery of Biological Images in use in Articles and Books

TBD

Artifacts in the of Content Creation of PRIOR ART

in original curations

Internal Use – subsets per BioMed e- Series in Medical Specialties

Asset Class VI

Team of Experts

BIOs Final Improvement Team (FIT)

Factor of Content Creation

Personal Agreement s to become Employment Contracts Post-Exit

Internal

Asset Class VII

Royalties on BioMed e- Series:Page downloads, Book borrowings and Book sale

111,645 page downloads in total on 3/9/2020

Current Account Receivables

Royalties Agreement with KDP

@Amazon

Derivative of Interest in Content (120,000

Pages download in 16 books

Asset Class VIII

Subscribers to the Website

2,554 on 3/29/2020

Potential Account Receivables

n/a

Drivers of Loyalty & Success

Asset Class IX

INTANGIBLE ASSETS

& Intrinsic Value = Good Will

TBD

Potential Account Receivables

External

e-Reputation

Asset Class X

e-VOICE PODCASTS

Audio Library

TBD

Potential Account Receivables

B2B & B2B & B2C

Asset

Classes

Type

Quantity

Business Model

Asset Protection

Transaction Type

Asset Classes

Unique Value Proposition

Key Paying Customers

Key Stakeholders

Unique Selling Point

Asset Class I

We create a new level of knowledge that is current and lively on the current issues and based on a discussion of multiple KOL

Legal, regulatory, Pharma R&D, Non academia, Gov, Journalists, media, Premium audience

academics, students, science addicts

Current high level accessible knowledge

Asset Class II

in depth as of day of publication knowledge collection of topic, background, good as a course or a journal club guide. State of the art, science based, outcome oriented KOL based perspective.

Legal, regulatory, pharma R&D, non academia, Gov, journalists and media, premium audience

Universities, Patient advocacy groups, Professional associations, Curriculum developers

current highly multiple domain specialized accessible knowledge

Asset Class III

In depth on publication day, knowledge collection of topic, depicts event spirit and highlights with KOL perspective and annotation, scientific documents and historical state of Science

Global Biotech & Healthcare Conference Organizers + Customers of Asset Class I+II

Conference Participants, Future Attendees & Participants Missing Conference Sessions

Real time, On demand, Event Tweet Collections

Asset Class IV

platform that allow harnessing the state of knowledge to produce a state of the art coverage of eventual or topic based current knowledge products to a specific targeted audience

New topics, new geographies knowledge community makers, LPBI new products pipeline

the global KOL community in health, life- sciences and pharma

unique, easy, proven, state of the art

Transaction Type

Unique Value Proposition

Key Paying Customers

Key Stakeholders

Unique Selling Point

Asset Class V

Selection done by Domain Experts for IP creation of original content

TBD

e-Readers, Publishers, Future Publishing Academics

Asset Class VI

Group of outcome-oriented KOLs in Health Care & Pharma Industry & Academia expertise

Human Capital asset

Asset Class VII

Global reach

e-Readers of Science e-Books

Scientist- contributors on FIT and Past contributors

Asset Class VIII

A reach into the top of the line Executives and KOLs in Pharma and Life sciences R&D

To be segmented and Targeted for Outreach and Outbound Marketing

Venture Owner

Top of the line, majority of the Global market leaders in Biotech

Asset Class IX

Product/Service Quality & Reputation

Acquirer and Its Customers

VERACITY SEEKERS and EVIDENCE BASED MEDICINE PROMOTERS

Asset Class X

Selection of most prominent Figures to be featured

Media Licensing Agreements

PBS, TV

Networks

Transaction Type

Unique Value Proposition

Key Paying Customers

Key Stakeholders

Unique Selling Point

Posted in LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management | Leave a Comment

Comments RSS

Leave a Reply Cancel reply

Enter your comment here...

Fill in your details below or click an icon to log in:

Email (required) (Address never made public)

Name (required)

Website

You are commenting using your WordPress.com account. ( Log Out / Change )

You are commenting using your Google account. ( Log Out / Change )

You are commenting using your Twitter account. ( Log Out / Change )

You are commenting using your Facebook account. ( Log Out / Change )

Cancel

Connecting to %s

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,054 other followers

Email Address:
Recent Posts
- Inflammation and potential links with the microbiome: Mechanisms of infection by SARS-CoV-2 January 24, 2021
- How do neurons form long term memories ? January 22, 2021
- 50th Annual Lewis S. Rosenstiel Award to Katalin Karikó and Drew Weissman for work on messenger RNA, modification of Nucleic Acids applied in the development of COVID-19 Vaccines January 22, 2021
- Plant Cells of Different Species Can Swap Organelles January 22, 2021
- Left Ventricular Volume Reduction and Reshaping as a Treatment Option for Heart Failure January 22, 2021
- Allon Klein, Harvard Medical School, and Aviv Regev, Genentech, Recipients of National Academy of Sciences James Prize in Science and Technology Integration 2021 Award January 19, 2021
- World Leaders to meet during Davos Agenda in a crucial year to rebuild trust January 18, 2021
- Joe Biden Announced Science Team Nominations for the New Administration January 17, 2021
- Potential Interest in LPBI Group’s BioMed e-Series January 17, 2021
- Dysregulation of ncRNAs in association with Neurodegenerative Disorders January 11, 2021
Archives
Archives
Categories
Categories
Meta

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Asset Class I-X, Type, Quantity, Business Model, Protection, Transaction Type, Unique Value Proposition, Key Paying Customers, Key Stakeholders and Unique Selling Point

Leave a Reply Cancel reply

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Asset Class I-X, Type, Quantity, Business Model, Protection, Transaction Type, Unique Value Proposition, Key Paying Customers, Key Stakeholders and Unique Selling Point

Share this:

Like this:

Related

Leave a Reply Cancel reply

Follow Blog via Email

Recent Posts

Archives

Categories

Meta